A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Recently, Ardestani et al.  published their excellent findings in this journal. They found that DNMT3A mutations alone do not affect the clinical outcomes of acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), but when accompanied by FLT3-ITD mutations, the overall survival (OS) was significantly reduced and the relapse rate increased. NPM1 mutations had no impact on either relapse-free survival or OS, but there was a significantdoi:10.4274/tjh.2018.0274 fatcat:cl5acr36wrhatossffe5vjqf6a